July 20, 2021
11 am to 12 pm EDT

Webinar Description:

Working with both Proteros and X-Chem will enable you to access quality protein, a suite of encoded chemical libraries, biophysics, biochemistry, structural biology and medicinal chemistry services for the delivery of Qualified Hits and/or Lead Candidates with solidly validated chemical matter to enable your downstream drug discovery efforts.

DNA-Encoded Chemistry enables you to perform a broad and unbiased sampling of chemical space in your search for novel chemical equity to initiate your next drug discovery program.

We will showcase a project that, through X-Chem and Proteros partnership, demonstrates the discovery and characterization of genuinely novel chemical equity.

Learning Objectives:

  • To bring awareness of X-Chem and Proteros combined capabilities and complete services for early stage drug discovery.


Anthony D Keefe, Ph.D.
Senior Vice President Alliance Management and Innovation
X-Chem, Inc.

Tony has twenty-four years of experience of working with encoded library platforms and was responsible for the design of the encoding architecture for the X-Chem platform and also for establishing its affinity-mediated selection platform and the processes by which selection outputs are deconvoluted and understood. Tony oversees all collaborations at X-Chem including with over half of the top twenty pharmaceutical companies, biotech and emerging companies and academic research institutes. During his academic career Tony was the first author of two Nature articles. Tony holds a BSc. In Chemistry from Exeter University, UK and a Ph.D. in Chemistry from Birmingham University, UK.

Debora Konz Makino, Ph.D.
Head of Discovery Solutions Business Unit
Proteros biostructures GmbH

Debora is responsible for the business unit involving all Proteros integrated services, including collaboration and partnerships with many of the top 20 pharmaceutical companies, startup and academic research institutes. Debora has over 20 years of experience in structural biology in both academic and CRO settings. Her successful career in academia, with two first author Nature articles and a Science paper, correlated with her positions of increasing responsibilities at CRO companies, supporting external R&D programs, identifying new technologies, and business strategies. She holds a B.S./M.S. in physics from the University of Sao Paulo, Ph.D. in biochemistry from the University of California, Irvine, and business certification from the Frankfurt School of Finance & Management.

Cost: No Cost!